Relay Therapeutics (RLAY) News Today $4.46 +0.14 (+3.24%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest UpdateRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 14,950,000 shares, an increase of 23.8% from the December 15th total of 12,080,000 shares. Based on an average daily volume of 2,080,000 shares, the days-to-cover ratio is presently 7.2 days.January 17 at 10:10 PM | marketbeat.comWe're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn RateJanuary 17 at 9:29 PM | finance.yahoo.comRelay Therapeutics' SWOT analysis: stock poised for growth amid fierce competitionJanuary 17 at 9:29 PM | msn.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Should You Sell?January 16 at 5:53 PM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Reaches New 12-Month Low - What's Next?Relay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Here's WhyJanuary 16 at 6:09 AM | marketbeat.comRelay Therapeutics: Buy Rating Amid Competitive Advances and Strategic OpportunitiesJanuary 15 at 3:26 AM | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 4.8% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?January 14 at 12:17 PM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Relay Therapeutics in a research report on Tuesday.January 14 at 8:05 AM | marketbeat.comRelay Therapeutics: Positioned for Success with Best-in-Class PI3Kα Inhibitor RLY-2608January 14 at 4:09 AM | markets.businessinsider.comAnalysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Price Target at $20.50January 14 at 1:24 AM | americanbankingnews.comBarclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Barclays PLC boosted its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 118.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 251,819 shares of the company's stock after purchasing an additionalJanuary 12, 2025 | marketbeat.comPotential acquisition of Scorpion positive for Relay, says BarclaysJanuary 11, 2025 | markets.businessinsider.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from AnalystsRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and ten have assigned a buy ratinJanuary 11, 2025 | marketbeat.comEli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesawsJanuary 10, 2025 | msn.comRelay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year Low - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Hits New 12-Month Low - Here's What HappenedJanuary 10, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8% - Should You Buy?Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.8% - Still a Buy?January 8, 2025 | marketbeat.comRelay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comPeter Rahmer Sells 16,576 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJanuary 7, 2025 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 16,576 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.45, for a total value of $73,763.20. Following the completion of the transaction, the insider now directly owns 308,754 shares in the company, valued at $1,373,955.30. This represents a 5.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.January 6, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 SharesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 32,156 shares of Relay Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $4.15, for a total transaction of $133,447.40. Following the completion of the transaction, the insider now owns 357,507 shares of the company's stock, valued at $1,483,654.05. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.January 6, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 39.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,517,516 shares of the company's stock after buJanuary 6, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 4,865 SharesJanuary 1, 2025 | insidertrades.comThomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 4,865 shares of the business's stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $4.42, for a total value of $21,503.30. Following the sale, the chief financial officer now directly owns 299,226 shares in the company, valued at $1,322,578.92. The trade was a 1.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.December 31, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - Time to Sell?December 31, 2024 | marketbeat.comIs Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?December 30, 2024 | msn.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Holdings Increased by Geode Capital Management LLCGeode Capital Management LLC grew its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 15.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,732,270 shares of the company's stock after acquiring an additional 367,473 shares durinDecember 29, 2024 | marketbeat.comBarclays PLC Acquires 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Barclays PLC lifted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 118.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,819 shares of the company's stock after purchasing an addiDecember 28, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 2.5% - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Down 2.5% - Here's WhyDecember 24, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stake Boosted by Franklin Resources Inc.Franklin Resources Inc. increased its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 3,883.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,396,842 shareDecember 22, 2024 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 100,000 Shares of StockDecember 19, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 100,000 SharesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 100,000 shares of the company's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $5.00, for a total value of $500,000.00. Following the completion of the transaction, the chief executive officer now directly owns 574,548 shares of the company's stock, valued at $2,872,740. The trade was a 14.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.December 18, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year Low - Here's What HappenedRelay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Here's What HappenedDecember 18, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by HighTower Advisors LLCHighTower Advisors LLC cut its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 48.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 154,920 shares of the company's stock after selling 148,425 shares during the quDecember 18, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 5.4% - Here's What HappenedRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4% - Should You Sell?December 17, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and ten have issuDecember 17, 2024 | marketbeat.comRelay Therapeutics, Inc. (RLAY): A Bull Case TheoryDecember 13, 2024 | insidermonkey.comJefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)December 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)December 12, 2024 | markets.businessinsider.comRelay Therapeutics (RLAY) Gets a Buy from BarclaysDecember 12, 2024 | markets.businessinsider.comJMP Securities Reiterates Market Outperform Rating for Relay Therapeutics (NASDAQ:RLAY)JMP Securities reissued a "market outperform" rating and set a $21.00 price target on shares of Relay Therapeutics in a research note on Thursday.December 12, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 26.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,035,789 shares of the company's stock after purchDecember 12, 2024 | marketbeat.comRelay Therapeutics Reports Promising Data on RLY-2608December 11, 2024 | markets.businessinsider.comRelay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free SurvivalDecember 11, 2024 | globenewswire.comRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer SymposiumDecember 9, 2024 | globenewswire.comPoint72 Asset Management L.P. Invests $9.55 Million in Relay Therapeutics, Inc. (NASDAQ:RLAY)Point72 Asset Management L.P. purchased a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,349,400 shares of the company's stock, valued at approximately $9,554,00December 8, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for RLAY FY2024 Earnings?Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Relay Therapeutics in a research report issued on Wednesday, December 4th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($2.47)December 6, 2024 | marketbeat.comFY2024 Earnings Forecast for RLAY Issued By Leerink PartnrsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Relay Therapeutics in a report issued on Tuesday, December 3rd. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per shareDecember 6, 2024 | marketbeat.comRelay Therapeutics, Elevar Therapeutics enter licensing agreementDecember 4, 2024 | markets.businessinsider.comMaven Securities LTD Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY)Maven Securities LTD bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 337,426 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comElevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsDecember 3, 2024 | globenewswire.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.290.72▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼134▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACAD News VCEL News XENE News MLTX News MOR News DNLI News SWTX News MRUS News ZLAB News BHC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLAY Stock Alerts